COVID-19 serology in nephrology healthcare workers
| Autor: | Alice Schmidt, Sonja Jansen-Skoupy, Barbara Holzer, Thomas Reiter, Robert Straßl, Gere Sunder-Plassmann, Sahra Pajenda, Ludwig Wagner, Manuela Födinger, Katharina A. Mayer, Martina Gaggl, Daniela Gerges, Irene Zimpernik, Johanna Atamaniuk, Christof Aigner |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Nephrology
medicine.medical_specialty Health Personnel Antibodies Viral medicine.disease_cause Asymptomatic Serology 03 medical and health sciences 0302 clinical medicine Seroepidemiologic Studies Internal medicine medicine Humans Seroprevalence 030212 general & internal medicine Antibody 030304 developmental biology Coronavirus 0303 health sciences Pandemic biology SARS-CoV-2 business.industry COVID-19 General Medicine medicine.disease Confidence interval Serology test biology.protein Original Article medicine.symptom business Kidney disease |
| Zdroj: | Wiener Klinische Wochenschrift |
| ISSN: | 1613-7671 0043-5325 |
| Popis: | Summary Background Chronic kidney disease patients show a high mortality in cases of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV‑2) infection. Thus, information on the sero-status of nephrology personnel might be crucial for patient protection; however, limited information exists about the presence of SARS-CoV‑2 antibodies in asymptomatic individuals. Methods We examined the seroprevalence of SARS-CoV‑2 IgG and IgM antibodies among healthcare workers of a tertiary care kidney center during the the first peak phase of the corona virus disease 2019 (COVID-19) crisis in Austria using an orthogonal test strategy and a total of 12 commercial nucleocapsid protein or spike glycoprotein-based assays as well as Western blotting and a neutralization assay. Results At baseline 60 of 235 study participants (25.5%, 95% confidence interval, CI 20.4–31.5%) were judged to be borderline positive or positive for IgM or IgG using a high sensitivity/low specificity threshold in one test system. Follow-up analysis after about 2 weeks revealed IgG positivity in 12 (5.1%, 95% CI: 2.9–8.8%) and IgM positivity in 6 (2.6%, 95% CI: 1.1–5.6) in at least one assay. Of the healthcare workers 2.1% (95% CI: 0.8–5.0%) showed IgG nucleocapsid antibodies in at least 2 assays. By contrast, positive controls with proven COVID-19 showed antibody positivity among almost all test systems. Moreover, serum samples obtained from healthcare workers did not show SARS-CoV‑2 neutralizing capacity, in contrast to positive controls. Conclusion Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV‑2 seroprevalence among asymptomatic individuals, while this was not the case among COVID-19 patients. Trial registration number CONEC, ClinicalTrials.gov number NCT04347694 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink